BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26787319)

  • 1. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
    Bhargava-Shah A; Foygel K; Devulapally R; Paulmurugan R
    Nanomedicine (Lond); 2016 Feb; 11(3):235-47. PubMed ID: 26787319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
    Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
    Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer.
    Paulmurugan R; Bhethanabotla R; Mishra K; Devulapally R; Foygel K; Sekar TV; Ananta JS; Massoud TF; Joy A
    Mol Cancer Ther; 2016 Feb; 15(2):221-31. PubMed ID: 26553061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
    Devulapally R; Sekar TV; Paulmurugan R
    Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring paclitaxel-loaded adenosine-conjugated PEGylated PLGA nanoparticles for targeting triple-negative breast cancer.
    Chaudhari D; Kuche K; Yadav V; Ghadi R; Date T; Bhargavi N; Jain S
    Drug Deliv Transl Res; 2023 Apr; 13(4):1074-1087. PubMed ID: 36528709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
    Devulapally R; Sekar NM; Sekar TV; Foygel K; Massoud TF; Willmann JK; Paulmurugan R
    ACS Nano; 2015 Mar; 9(3):2290-302. PubMed ID: 25652012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line.
    Byrne CE; Astete CE; Vaithiyanathan M; Melvin AT; Moradipour M; Rankin SE; Knutson BL; Sabliov CM; Martin EC
    Nanomedicine (Lond); 2020 Apr; 15(10):981-1000. PubMed ID: 32238059
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
    Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
    Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer.
    Sims LB; Curtis LT; Frieboes HB; Steinbach-Rankins JM
    J Nanobiotechnology; 2016 Apr; 14():33. PubMed ID: 27102372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
    Chen J; Li S; Shen Q; He H; Zhang Y
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
    Xin L; Zhang HT; Yang WF; Li YF; Liu C
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
    Tao W; Zeng X; Liu T; Wang Z; Xiong Q; Ouyang C; Huang L; Mei L
    Acta Biomater; 2013 Nov; 9(11):8910-20. PubMed ID: 23816645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
    Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
    J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
    Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
    Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
    Devulapally R; Foygel K; Sekar TV; Willmann JK; Paulmurugan R
    ACS Appl Mater Interfaces; 2016 Dec; 8(49):33412-33422. PubMed ID: 27960411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
    Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
    Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
    Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
    J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of Apoptosis-inducing Piperine to Triple-negative Breast Cancer Cells
    Rad JG; Hoskin DW
    Anticancer Res; 2020 Feb; 40(2):689-694. PubMed ID: 32014909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.
    Scully MA; Wilkins DE; Dang MN; Hoover EC; Aboeleneen SB; Day ES
    Mol Pharm; 2023 Aug; 20(8):3895-3913. PubMed ID: 37459272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.